Literature DB >> 2865030

Effect of alprazolam on digoxin kinetics and creatinine clearance.

H R Ochs, D J Greenblatt, B Verburg-Ochs.   

Abstract

Eight healthy men received a single, 1.25 mg dose of digoxin on two occasions, once in an otherwise drug-free control state and again while concurrently receiving alprazolam, 1.5 mg/day. There was no significant difference between control and alprazolam conditions in digoxin volume of distribution (11.0 vs. 11.2 L/kg), elimination t1/2 (46 vs. 41 hours), or total clearance from serum (2.8 vs. 3.6 ml/min/kg). Alprazolam coadministration slightly reduced mean 96-hour urinary excretion of digoxin (37.6% vs. 30.9% of dose; P less than 0.01), but there was no significant difference between treatment conditions in projected total cumulative excretion of digoxin (45.2% vs. 40.9% of dose) or in renal clearance of digoxin (1.23 vs. 1.44 ml/min/kg). Creatinine clearance also did not differ between the control and alprazolam conditions (164 vs. 142 ml/min). Thus therapeutic doses of alprazolam do not significantly alter digoxin clearance in healthy man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865030     DOI: 10.1038/clpt.1985.230

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 2.  Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.

Authors:  A D Mooradian
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 3.  Chest pain and angiographically normal coronary arteries. Implications for treatment.

Authors:  V Mukerji; B D Beitman; M A Alpert
Journal:  Tex Heart Inst J       Date:  1993

Review 4.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

5.  Validation of a transparent decision model to rate drug interactions.

Authors:  Elmira Far; Ivanka Curkovic; Kelly Byrne; Malgorzata Roos; Isabelle Egloff; Michael Dietrich; Wilhelm Kirch; Gerd-A Kullak-Ublick; Marco Egbring
Journal:  BMC Pharmacol Toxicol       Date:  2012-08-20       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.